



Striatal Dopamine D₂-Muscarinic Acetylcholine M₁ Receptor–Receptor Interaction in a Model of Movement Disorders

René A. J. Crans^{1,2}, Elise Wouters¹, Marta Valle-León^{2,3}, Jaume Taura^{2,3}, Caio M. Massari^{2,4}, Víctor Fernández-Dueñas^{2,3}, Christophe P. Stove^{1*†} and Francisco Ciruela^{2,3*†}

¹ Laboratory of Toxicology, Department of Bioanalysis, Ghent University, Ghent, Belgium, ² Unitat de Farmacologia, Departament Patologia i Terapèutica Experimental, Facultat de Medicina, IDIBELL-Universitat de Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain, ³ Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain, ⁴ Programa de Pós-graduação em Bioquímica, Centro de Ciências Biológicas, Universidade Federal de Santa Catarina, Florianópolis, Brazil

OPEN ACCESS

Edited by:

Luis F. Callado,
University of the Basque Country,
Spain

Reviewed by:

Luca Ferraro,
University of Ferrara, Italy
Melissa L. Perreault,
University of Guelph, Canada

*Correspondence:

Christophe P. Stove
christophe.stove@ugent.be
Francisco Ciruela
fciruela@ub.edu

† These authors have contributed
equally to this work

Specialty section:

This article was submitted to
Neuropharmacology,
a section of the journal
Frontiers in Pharmacology

Received: 13 December 2019

Accepted: 11 February 2020

Published: 13 March 2020

Citation:

Crans RAJ, Wouters E, Valle-León M, Taura J, Massari CM, Fernández-Dueñas V, Stove CP and Ciruela F (2020) Striatal Dopamine D₂-Muscarinic Acetylcholine M₁ Receptor–Receptor Interaction in a Model of Movement Disorders. *Front. Pharmacol.* 11:194. doi: 10.3389/fphar.2020.00194

Parkinson's disease (PD) is a neurodegenerative disorder characterized by motor control deficits, which is associated with the loss of striatal dopaminergic neurons from the substantia nigra. In parallel to dopaminergic denervation, there is an increase of acetylcholine within the striatum, resulting in a striatal dopaminergic–cholinergic neurotransmission imbalance. Currently, available PD pharmacotherapy (e.g., prodopaminergic drugs) does not reinstate the altered dopaminergic–cholinergic balance. In addition, it can eventually elicit cholinergic-related adverse effects. Here, we investigated the interplay between dopaminergic and cholinergic systems by assessing the physical and functional interaction of dopamine D₂ and muscarinic acetylcholine M₁ receptors (D₂R and M₁R, respectively), both expressed at striatopallidal medium spiny neurons. First, we provided evidence for the existence of D₂R–M₁R complexes via biochemical (i.e., co-immunoprecipitation) and biophysical (i.e., BRET¹ and NanoBIT[®]) assays, performed in transiently transfected HEK293T cells. Subsequently, a D₂R–M₁R co-distribution in the mouse striatum was observed through double-immunofluorescence staining and AlphaLISA[®] immunoassay. Finally, we evaluated the functional interplay between both receptors via behavioral studies, by implementing the classical acute reserpine pharmacological animal model of experimental parkinsonism. Reserpinized mice were administered with a D₂R-selective agonist (sumanirole) and/or an M₁R-selective antagonist (VU0255035), and alterations in PD-related behavioral tasks (i.e., locomotor activity) were evaluated. Importantly, VU0255035 (10 mg/kg) potentiated the antiparkinsonian-like effects (i.e., increased locomotor activity and decreased catalepsy) of an ineffective sumanirole dose (3 mg/kg). Altogether, our data suggest the existence of putative striatal D₂R/M₁R heteromers, which might be a relevant target to manage PD motor impairments with fewer adverse effects.

Keywords: D₂R, M₁R, sumanirole, VU0255035, striatum, Parkinson's disease

INTRODUCTION

Parkinson's disease (PD) is a common movement disorder that is clinically characterized by motor control deficits, such as bradykinesia, muscular rigidity, resting tremors, and postural instability (Mhyre et al., 2012). Approximately, 1% of the population older than 60 years is affected by PD. The major pathophysiological PD hallmark is the loss of dopaminergic neurons projecting from the substantia nigra pars compacta (Hisahara and Shimohama, 2011; Dexter and Jenner, 2013), which leads to dopamine (DA) depletion within the striatum. L-3,4-dihydroxyphenylalanine (L-DOPA) is an effective DA replacement strategy, which efficiently reverses motor control deficits at the early stages of the disorder. However, long-term L-DOPA therapy (>5–10 years) is commonly associated with adverse motor complications, such as dyskinesia and efficacy fluctuations, thus reducing the patient's quality of life (Jenner, 2003; Kalia and Lang, 2015). Currently, DA receptor agonists (i.e., pramipexole and ropinirole) are considered the first choice in PD therapy, as monotherapy or adjuvants to L-DOPA (Fox et al., 2011; Fox et al., 2018). Again, these agonists are effective at the early stages, but they eventually fail reducing motor complications (Jenner, 2003; Hisahara and Shimohama, 2011). Interestingly, before L-DOPA was extensively prescribed, anticholinergics were the first-line therapeutics in PD (Carlsson et al., 1957; Katzenschlager et al., 2003). The cholinergic system plays a pivotal role in regulating striatal functions by modulating the excitability of GABAergic medium spiny neurons (MSNs), which constitute nearly 95% of the striatal neuronal population (Lv et al., 2017). Nowadays, anticholinergics (i.e., biperiden) are eventually used as adjuvant drugs in PD management, besides their adverse effects (i.e., nausea, cognitive impairments, dry mouth, urinary retention, and blurred vision). Importantly, some of these adverse effects are likely due to a lack of muscarinic acetylcholine receptor (mAChR) subtype selectivity, because both M₂R and M₃R are blocked (Chen and Swope, 2007; Pedrosa and Timmermann, 2013). Recently, cholinergic modulation of striatal functions has gained renewed interest because of the development of compounds targeting specific mAChR subtypes (Xiang et al., 2012; Shen et al., 2015; Ztaou et al., 2016; Lv et al., 2017; Chambers et al., 2019).

Five distinct mAChR subtypes (M₁R–M₅R) have been identified, which are classified into two groups, based on pharmacological and molecular characteristics. The excitatory M₁-like receptors (M₁R, M₃R, and M₅R) transduce their signals via G_{q/11} proteins, whereas the inhibitory M₂-like receptors (M₂R and M₄R) are coupled to G_{i/o} proteins (Zhang et al., 2002; Bordia and Perez, 2019). All subtypes are present in the striatum, with M₁R and M₄R being highly expressed and modulating the excitability of GABAergic MSNs (Hersch et al., 1994; Yan et al., 2001). In general, two types of MSNs have been distinguished: (i) dopamine D₂ receptors (D₂Rs) expressing MSNs (i.e., D₂R-MSNs), which belong to the striatal indirect pathway (Gagnon et al., 2017); and (ii) dopamine D₁ receptors (D₁Rs) containing MSNs (i.e., D₁R-MSNs) constituting the striatal direct pathway. The D₁R-MSNs express postsynaptic

M₄Rs, whereas M₁Rs are expressed by both D₁R-MSNs and D₂R-MSNs. Thereby, within the striatum, tonically active cholinergic interneurons (ChIs), which constitute 1% to 2% of the total striatal neuronal population (Bolam et al., 1984; Pisani et al., 2007), release acetylcholine (ACh) through widely arborizing axons with large terminal fields that modulate the MSNs via M₁Rs and M₄Rs (Graybiel, 1990; Mesulam et al., 1992; Contant et al., 1996). Interestingly, the modulation of MSNs with a selective M₁R antagonist resulted in antiparkinsonian-like effects in a number of rat models of movement disorders (Xiang et al., 2012). In addition, the blockade of M₁R, M₄R, or ChI signaling improved the motor functions in 6-hydroxydopamine-lesioned mice (Ztaou et al., 2016). Furthermore, systemic administration of scopolamine (a non-selective mAChR antagonist) modulated the DA turnover and reduced D₂R affinity of raclopride in monkey brains (Tsukada et al., 2000). These studies suggest an intense neuronal interaction between dopaminergic and cholinergic systems, where normal motor functions may require a fine-tuned and coordinated control (Di Chiara et al., 1994; Calabresi et al., 2000; Zhang et al., 2002). The extent to which both neurotransmission systems specifically integrate at a molecular and/or functional level is of high interest for the development of novel multimodal pharmacological therapies to manage PD (Fuxe et al., 2012).

Here, we describe a novel interaction between the D₂R and M₁R in the striatum, which may eventually harmonize with those previously described for D₂R (Cabello et al., 2009; Lukasiewicz et al., 2010; Borroto-Escuela et al., 2013; Bonaventura et al., 2014; Fernandez-Duenas et al., 2015; Rico et al., 2017; Vasudevan et al., 2019). In addition, we evaluated the antiparkinsonian efficacy of a combined D₂R agonist (i.e., sumanirole) and M₁R antagonist (i.e., VU0255035) treatment using the reserpine animal model of experimental parkinsonism. To our knowledge, this study is the first to demonstrate a molecular interaction and a functional interplay between D₂R and M₁R.

MATERIALS AND METHODS

Plasmid Construction

The plasmids pFLAG-D₂R, pHA-M₁R, pD₂R-Rluc, pM₁R-YFP, and pEYFP were a kind gift of Dr. Kjell Fuxe (Karolinska Institutet, Stockholm, Sweden). The sequence encoding the human M₁R (NM_000738.3) was polymerase chain reaction-amplified using primers containing specific restriction sites (*Hind*III and *Eco*RI, 5'-GCTTAAGCTTATGAACACTTCAG-3' and 5'-TCGAGAATTCGCGCATTGGC-3') and cloned into the *Hind*III/*Eco*RI sites of the NanoBiT[®] vector NB MCS1 (Promega, Madison, WI, United States). The construct was verified by restriction digest and Sanger sequencing (Eurofins Genomics, Ebersberg, Germany). This resulted in the fusion of the split NanoLuciferase (NL) fragment LargeBiT (LgBiT; 18 kDa) to the C-terminus of M₁R. The constructs of cannabinoid types 1 and 2 receptors (CB₁R and CB₂R, respectively) and D₂R fused with LgBiT or Small BiT (SmBiT; 1 kDa) were previously developed and described by our research group (Cannaert et al., 2016; Wouters et al., 2019a).

Cell Culture and Transient Transfection

Human embryonic kidney 293T (HEK293T; American Type Culture Collection, Manassas, VA, United States) cells were maintained in Dulbecco modified Eagle medium (DMEM; Thermo Fisher Scientific, Pittsburg, PA, United States) supplemented with GlutaMAX, 10% fetal bovine serum (FBS; Merck KgaA, Darmstadt, Germany), streptomycin (100 $\mu\text{g}/\text{mL}$), and penicillin (100 $\mu\text{g}/\text{mL}$) in a controlled environment (37°C, 98% humidity, and 5% CO_2). Prior to transfection, cells were cultured in 10-cm dishes (co-immunoprecipitation) or six-well plates [Bioluminescence Resonance Energy Transfer¹ (BRET¹) and NanoLuciferase Binary Technology (NanoBiT[®]) assays] in 10 or 2 mL DMEM supplemented with 10% FBS, respectively. The HEK293T cells were transiently transfected using the polyethylenimine (Sigma-Aldrich, St. Louis, MO, United States) method. In all assays, medium was refreshed with DMEM + 10% FBS after 5 h.

Co-immunoprecipitation

HEK293T cells were transfected with 5 μg of the constructs containing pFLAG-D₂R and/or pHA-M₁R. When necessary, 5 μg of the empty vector pcDNA3.1 was co-transfected to maintain a total amount of 10 μg DNA per 10-cm dish. After 48 h, cells were washed three times with ice-cold phosphate-buffered saline (PBS; 1.47 mM KH_2PO_4 , 8.07 mM Na_2HPO_4 , 137 mM NaCl, 0.27 mM KCl with pH 7.2), harvested, and centrifuged, after which the pellet was stored at -80°C until further use. The cells were homogenized in ice-cold 50 mM Tris-HCl (pH 7.4) with the Polytron at setting six for two periods of 10 s. Subsequently, the homogenates were transferred to 1.5-mL Eppendorf and centrifuged at $12,000 \times g$ for 30 min at 4°C. Then, all supernatant was removed, and the pellets were lysed in radioimmunoprecipitation assay (RIPA) buffer [150 mM NaCl, 25 mM Tris-HCl (pH 7.5), 1% sodium deoxycholate, 1% NP-40, and 0.1% sodium dodecyl sulfate (SDS)], supplemented with freshly added protease inhibitors (2.5 g/mL aprotinin, 1 mM PEFA-block, 10 g/mL leupeptin), for 1 h while rotating at 4°C. The samples were centrifuged at $12,000 \times g$ for 20 min at 4°C. Next, the supernatant of each sample was transferred to a new Eppendorf, and the protein concentrations were determined using the bicinchoninic acid (BCA) assay (Pierce Biotechnology, Rockford, IL, United States). Thereafter, all samples were diluted with RIPA buffer to obtain equal protein concentrations with a final volume of 500 μL . An amount of 10% for each sample (i.e., lysate) was denatured at 37°C for 10 min in $4 \times$ Laemmli [5% SDS, 50% glycerol, 65 mM Tris-HCl (pH 6.8) and 0.2% bromophenol blue], supplemented with freshly added 10% β -mercaptoethanol. The lysates were loaded onto a 10% polyacrylamide 10-well gel and resolved via SDS-polyacrylamide gel electrophoresis (SDS-PAGE). Subsequently, the proteins were blotted onto a nitrocellulose membrane (Amersham Protran 0.45 NC; GE Healthcare Life Sciences, Freiburg, Germany) and subjected to immunoblot analysis, as described below. The other 90% of each sample [i.e., immunoprecipitates (IPs)] was used for immunoprecipitation through adding 2 μg mouse anti-FLAG

antibody (clone M2; Sigma-Aldrich) or mouse anti-HA antibody (clone 16B12; Abcam, Cambridge, United Kingdom). After 1.5 h of rotation, 20 μL of washed immobilized Protein-A UltraLink[®] Resin (#53139; Thermo Fisher Scientific) was added to the IPs, and the rotation continued for 1.5 h at 4°C. Then, the beads were washed three times with RIPA buffer supplemented with the freshly added protease inhibitors. The proteins were eluted and denatured from the beads by heating the samples for 10 min at 37°C in RIPA buffer and $4 \times$ Laemmli supplemented with freshly added 10% β -mercaptoethanol. All IP eluates were subjected to SDS-PAGE electrophoresis and immunoblotting, as described above.

Immunoblots containing lysates or IPs were blocked in PBS with Licor blocking buffer (1:1; LI-COR Biosciences, Lincoln, NE, United States) at room temperature (RT) for 1 h. Then, the immunoblots were incubated with rabbit anti-HA (1:2,000, #GTX29110; Genetex, Irvine, CA, United States) or rabbit anti-FLAG (1:1000, #PA1-984B; Thermo Fisher Scientific) antibodies in 1:1 Licor blocking buffer-PBST (PBS with 0.05% Tween 20) overnight at 4°C. The blots were washed three times with PBST for 10 min at RT. Next, the blots were incubated with donkey anti-rabbit secondary antibodies (1:15,000), conjugated to IRDye680RD or IRDye800CW (LI-COR Biosciences), for 1 h at RT. After incubation, the blots were washed three times with PBST and two times with PBS, each for 10 min at RT, protected from the light. Protein bands were visualized by the Odyssey imaging system (LI-COR Biosciences).

Bioluminescence Resonance Energy Transfer¹ Assay

HEK293T cells were transfected with a constant amount of pD₂R-Rluc (200 ng) and increasing amounts of pM₁R-YFP or pEYFP (0–1,000 ng). Equal DNA ratios were maintained with co-transfection of the empty vector pcDNA3.1, which equilibrated the total amount of transfected DNA. Forty-eight hours posttransfection, the cells were washed three times with PBS, detached, and resuspended in Hanks balanced salt solution (HBSS; Thermo Fisher Scientific). An aliquot was used to determine the protein concentrations via the BCA assay, to control the number of cells. All cell suspensions were diluted to a density corresponding to a final protein concentration of 600 ng/ μL . Cell suspensions (corresponding to 20 μg protein) were distributed in duplicates into white and black 96-well microplates (#3600 and #3650; Corning, Stockholm, Sweden) for BRET¹ and fluorescence measurements, respectively. The substrate, *h*-coelenterazine (Molecular Probes, Eugene, OR, United States), was added at a 5 μM final concentration. After 1 min (BRET¹) and 10 min (Rluc total), the signals were measured using the ClarioSTAR microplate reader (BMG Labtech, Ortenberg, Germany) through the sequential integration of signal detection at 475 nm (445–505 nm) and 530 nm (500–560 nm). The net BRET¹ ratio was expressed as a ratio of the light intensity at 530 nm over 475 nm by subtracting the background signal, which was detected when D₂R-Rluc was only expressed with pcDNA3.1. The BRET¹ curve was obtained by fitting the data points to a non-linear regression equation

assuming a single binding site using GraphPad Prism version 6.00 (San Diego, CA, United States).

NanoLuciferase Binary Technology[®] Assay

HEK293T cells were transfected with constructs encoding for pM₁R-LgBiT (200 ng) and pD₂R-SmBiT (200 ng). As negative controls, the cells were transfected with a combination of pM₁R-LgBiT and pCB₁R-SmBiT or pD₂R-SmBiT and pCB₂R-LgBiT, each with DNA concentrations of 200 ng. The functionality of the CB₁R-SmBiT and CB₂R-LgBiT constructs was demonstrated before (Cannaert et al., 2016). In all conditions, the construct encoding for the fluorescent protein Venus was co-transfected (5% of the total DNA transfected). The NanoBiT[®] assay was performed as described previously (Wouters et al., 2019a). Briefly, 48 h posttransfection, the cells were washed two times with PBS, detached, and centrifuged for 5 min at 1,000g at RT. Protein concentrations were determined on an aliquot via the BCA assay, and cell suspensions, normalized for cell number (via a corresponding protein concentration of 600 ng/μL), were diluted in HBSS. Following a 20-fold dilution of the Nano-Glo[®] Live Cell reagent (#N2011; Promega) containing the luminescent substrate furimazine in aqueous Nano-Glo LCS dilution buffer, 25 μL of the diluted substrate was added to the wells of a 96-well plate containing 100 μL cell suspension. Fluorescence (508–548 nm) or luminescence (440–480 nm) emission was measured with the ClarioSTAR microplate reader in black or white 96-well plates (#3650 and #3600; Corning), respectively. The luminescence data were normalized for the measured fluorescence signals to avoid signal fluctuations due to variations in transfection efficiencies.

Animals

Caesarean derived 1 (CD-1) mice (Janvier Labs, Le Genest-Saint-Isle, France), D₂R knockout (D₂R KO) CD-1, and M₁R knockout (M₁R KO) C57BL/6J mice were generated as described previously (Fisahn et al., 2002; Taura et al., 2017). Animals were housed and tested in compliance with the guidelines described in the Guide for the Care and Use of Laboratory Animals (Clark et al., 1997) and following the European Communities Council Directive (2010/63/EU), FELASA, and ARRIVE guidelines. The animals were conventionally housed in groups of four or five in a temperature-controlled (22°C) and humidity-controlled (66%) environment under a 12/12-h light–dark cycle, where food and water intake was *ad libitum*. The study protocol was approved by the Ethical Committee on Animal Use and Care of the University of Barcelona (CEEA/UB). All efforts were made to minimize animal suffering and the number of animals used in this study. Behavioral tests were performed with wild-type (WT) mice aged 5 months, weighing 40 to 55 g, between 12:00 and 18:00.

Double Immunofluorescence Staining

M₁R KO mice were kindly provided by Dr. Adrian James Mogg (Eli Lilly and Company Ltd., Windlesham, United Kingdom) with permission of Dr. Jurgen Wess {National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes

of Health (NIH), Bethesda, MD, United States]. These mice were anesthetized and perfused intracardially with 50 to 200 mL of ice-cold 4% formaldehyde solution (Sigma-Aldrich) in PBS. Subsequently, the brains were postfixed in 4% formaldehyde solution overnight at 4°C. D₂R KO and WT littermate fixed mouse brains were a kind gift from Dr. Jean-Martin Beaulieu (Centre de recherche en Santé Mentale de Québec, Québec, QC, Canada). Coronal brain sections (50 μm) were made with the Vibratome 1200S (Leica Lasertechnik GmbH, Heidelberg, Germany). Finally, the slices were collected and stored in antifreeze solution (30% glycerol, 30% ethylene glycol in PBS with pH 7.2) at -20°C until further processing. The coronal brain slices of WT, D₂R KO, and M₁R KO mice were washed three times with PBS and permeabilized with 0.3% Triton X-100 in PBS for 2 h at RT. Then, blocking was performed by incubating the slices with washing solution (PBS with 0.05% Triton X-100) containing 5% normal donkey serum (NDS; Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, United States) for 2 h at RT. Subsequently, the slices were incubated overnight at 4°C with rabbit anti-M₁R polyclonal (1:300, #mACHR-M1-Rb-Af340; Frontier Institute Co., Ltd., Shinko-nishi, Ishikari, Hokkaido, Japan) and guinea pig anti-D₂R polyclonal (1:300, #D2R-GP-Af500; Frontier Institute Co., Ltd.) antibodies in washing solution with 1% NDS. In parallel, overnight incubations of WT brain slices only in washing solution served as additional negative controls. After overnight incubation, the slices were washed three times with washing solution containing 1% NDS for 10 min at RT. Next, slices were incubated with Alexa Fluor[®] 488-conjugated donkey anti-guinea pig (1:400, #706-545-148; Jackson ImmunoResearch Laboratories) and Cy3-conjugated donkey anti-rabbit (1:400, #711-166-152, Jackson ImmunoResearch Laboratories) antibodies in washing solution with 1% NDS for 2 h at RT. Then, the slices were washed three times with washing solution for 10 min at RT and stained with 4,6-diamidino-2-phenylindole (DAPI; 1 μg/mL, #D9542; Sigma-Aldrich) for 15 min at RT. Finally, slices were washed twice with washing solution, twice with PBS for 10 min at RT, and preserved in Vectashield (#H-1000; Vector Laboratories, Burlingame, CA, United States). Images were captured with a Zeiss laser scanning microscope 880 (Carl Zeiss AG, Jena, Germany).

AlphaLISA[®] Immunoassay

The AlphaLISA[®] immunoassay was performed as previously described (Fernandez-Duenas et al., 2019). Briefly, WT and D₂R KO animals were euthanized by cervical dislocation, followed by dissection of striata on an ice-cold plate. Then, striatum was rapidly homogenized in ice-cold 50 mM Tris-HCl (pH 7.4) with a Polytron at setting six for three periods of 10 s. The homogenate was centrifuged at 1,000 × g for 10 min, and the supernatant was transferred to a new Eppendorf. The protein concentrations were determined with the BCA assay, and the membrane fractions were centrifuged at 12,000 × g for 30 min. The pellets were resuspended in assay buffer [20 mM MgCl₂, 130 mM NaCl, 0.2 mM EDTA, 0.1 mg/mL saponin, and 0.5% immunoglobulin G (IgG)-free bovine serum albumin] to a final protein concentration of 1.5 μg/μL. Donkey anti-guinea pig IgGs (#706-005-148; Jackson ImmunoResearch

Laboratories) were conjugated to the acceptor beads (#6762001; Perkin Elmer, Waltham, MA, United States), according to the manufacturer's instructions. Subsequently, 10 μ L of each striatal membrane in assay buffer was distributed in triplicate into a white 384-well plate (384 Well Small Volume HiBase Microplates; Greiner Bio-one, Kremsmünster, Austria) and stored for 1 h at 4°C. Subsequently, the membranes were incubated with rabbit anti-M₁R polyclonal (10 nM, #mAChR-M1-Rb-Af340; Frontier Institute Co., Ltd.) and guinea pig anti-D₂R polyclonal (10 nM, #D2R-GP-Af500; Frontier Institute Co., Ltd.) antibodies in assay buffer overnight at 4°C. In the WT-negative controls, only the anti-M₁R antibody was added, whereas the D₂R KO-negative controls were incubated with assay buffer overnight at 4°C. Next, acceptor beads (40 μ g/mL) were added to each well for 1 h. Then, the anti-rabbit IgG alpha donor beads (40 μ g/mL, #AS105D; Perkin Elmer) were added and mixed with the acceptor beads by pipetting up and down. Any prolonged light exposure was avoided. Finally, after 1-h incubation, the donor beads were excited (640–720 nm), and acceptor beads emission (597–633 nm) was measured with the ClarioSTAR microplate reader.

Locomotor Activity Tests

Mice were administered subcutaneously (s.c.) with reserpine (3 mg/kg; Sigma-Aldrich) or vehicle (saline with 5% Tween 20, s.c.) 20.5 \pm 2 h before the test. Then, mice were administered with vehicle [saline with 5% dimethyl sulfoxide (DMSO) and 5% Tween 20, i.p.], sumanirole (1, 3, or 10 mg/kg, i.p.; Sigma-Aldrich) and/or VU0255035 (10 mg/kg, i.p.; Tocris Biosciences, Bristol, United Kingdom) 10 min before each locomotor activity test. The mice were evaluated for drug-induced locomotor activity as described previously (Taura et al., 2017). Briefly, non-habituated mice were placed in the center of an activity field apparatus (30 \times 30 cm, surrounded by four 50-cm-high black walls) equipped with a camera above to record activity. Exploratory behavior of the animals was recorded for 85 min. The distance traveled was analyzed using the Spot tracker function from ImageJ (NIH). All locomotor activity tests were performed in a sound attenuated room, illuminated by light of 15 lux. After each trail, the apparatus was cleaned with 70% alcohol and rinsed with water.

Horizontal Bar Test

Catalepsy was induced in mice by the administration of reserpine (3 mg/kg, s.c.) overnight (20.5 \pm 2 h). Vehicle, sumanirole (1, 3, or 10 mg/kg, i.p.) and/or VU0255035 (10 mg/kg, i.p.) was administered, and 1.5 h later, catalepsy was measured as described previously (Massari et al., 2017; Taura et al., 2017). Briefly, using a stopwatch with a cutoff time of 120 s, the duration of an abnormal upright posture was measured, in which the forepaws of the mouse were placed on a horizontal wooden bar (0.6-cm diameter) that was located 4.5 cm above the floor.

Tremulous Jaw Movements

Mice were administered reserpine (3 mg/kg, s.c.) or vehicle (saline with 5% Tween 20, s.c.). Subsequently, vehicle (saline with 5% DMSO and 5% Tween 20, i.p.), sumanirole (1–10 mg/kg, i.p.), and/or VU0255035 (10 mg/kg, i.p.) was administered 1.5 h

before the test and 22 \pm 2 h after reserpine treatment. The tremulous jaw movements (TJMs) were measured with hand-operated counters, as described previously (Massari et al., 2017). Briefly, the mice were placed individually in a glass cylinder (13-cm diameter) and allowed to habituate for 10 min. Mirrors were placed under and behind the cylinder to allow observation when the animal faced away from the observer. Tremulous jaw movements were defined as rapid vertical deflections of the lower jaw that resembled chewing, but were not directed to any particular stimulus (Salamone et al., 1998). The incidence of these oral movements was measured continuously for 10 min, but were discounted during grooming.

Statistical Analysis


The number of biological replicates (n) in each experimental condition is indicated in the figure legends. Data of behavioral studies are expressed as the mean \pm SEM; all the other data are presented as the mean \pm SD. Numerical data were imported to GraphPad Prism version 6.00 for Windows (GraphPad Software, La Jolla, CA, United States). Statistical analysis of cellular or tissue data was performed using the Mann–Whitney *U* test or the non-parametric analysis of variance (ANOVA) by ranks of Kruskal–Wallis test followed by the Dunn multiple-comparisons *post hoc* test. Normal distributions of the behavioral data were inferred through the D'Agostino–Pearson normality test. Subsequently, behavioral data were analyzed with the one-way ANOVA or the two-way repeated-measures ANOVA followed by the Tukey or Dunnett multiple-comparisons *post hoc* test. *p* \leq 0.05 was considered as statistically significant.

RESULTS

D₂R–M₁R Interaction in HEK293T Cells

The ability of D₂R and M₁R to physically interact in living cells was assessed by biochemical and biophysical assays. First, co-immunoprecipitation experiments were performed in transiently transfected HEK293T cells. Interestingly, when HA-M₁R was immunoprecipitated from FLAG-D₂R and HA-M₁R co-transfected HEK293T cells, a specific immunoreactive band of 90 to 100 kDa corresponding to FLAG-D₂R was detected (Figure 1A, IPs). It is important to note that this band was not observed when the cells were transfected with a single receptor plus an empty plasmid or from an extract mix of separate transfected cells. Moreover, the D₂R and M₁R constructs were properly expressed in the whole setup (Figure 1A, lysates). These results indicate that D₂R and M₁R are expressed within the same membrane context and are prone to interact.

Subsequently, the existence of D₂R–M₁R complexes was verified by means of BRET¹ saturation assays. Accordingly, HEK293T cells were co-transfected with a constant amount of the D₂R-Rluc construct and increasing concentrations of M₁R-YFP or YFP plasmids (Figure 1B). A positive BRET signal was observed when D₂R-Rluc and M₁R-YFP were co-expressed, due to the energy transfer between Rluc and YFP. Conversely, in cells co-expressing D₂R-Rluc and YFP, no BRET¹ signal was observed. Overall, the BRET¹ data demonstrated that D₂R and



M₁R are in close proximity (<10 nm), thus supporting the existence of D₂R–M₁R complexes in living cells (Cottet et al., 2012; Dacres et al., 2012).

Finally, we implemented the complementation-based NanoBiT[®] assay to further validate the D₂R–M₁R interaction in HEK293T cells (Figure 1C). This assay utilizes two inactive fragments of a split NL, which, when fused to two interacting proteins, come into close proximity and reassemble into a functional protein (Wouters et al., 2019b). As shown in Figure 1C, co-expression of M₁R and D₂R fused to the large and small subunits of a split NL (M₁R–LgBiT and D₂R–SmBiT, respectively) yielded a high luminescent signal (Figure 1C) when compared to HEK293T cells expressing either constructs for M₁R and CB₁R (M₁R–LgBiT + CB₁R–SmBiT) or D₂R and CB₂R (D₂R–SmBiT + CB₂R–LgBiT), as previously reported (Wouters et al., 2019a). In addition, very low signals were observed in

cells expressing either M₁R (19 ± 3.5) or D₂R (9 ± 1.7), along with HaloTag–SmBiT or HaloTag–LgBiT, respectively. Altogether, our results are compatible with the formation of D₂R/M₁R heteromer formation by ectopically expressed M₁R and D₂R in HEK293T cells.

Co-distribution of D₂R and M₁R in the Mouse Striatum

Once the existence of D₂R–M₁R complexes in a heterologous expressing system was demonstrated, we aimed to verify whether this interaction might also occur in native tissue. To this end, we first analyzed D₂R and M₁R expression in mouse striatum by double-immunofluorescence staining. The specificity of the anti-D₂R and anti-M₁R antibodies was verified by using striatal slices from D₂R- and M₁R-deficient mice (D₂R KO and

M₁R KO, respectively) (**Supplementary Figures S1 and S2**). High-magnification images of the dorsal striatum from WT mice showed a high degree of D₂R and M₁R co-distribution (**Figure 2A**, arrows). Subsequently, to further demonstrate a close proximity (<200 nm) between both receptor types, we applied an AlphaLISA[®] immunoassay, as described previously (Fernandez-Duenas et al., 2019). Briefly, striatal membrane extracts were first incubated with specific primary antibodies against the receptor, which can be recognized by secondary antibodies tagged with beads able to engage in an energy transfer after the production of a singlet oxygen (Fernandez-Duenas et al., 2019). A significant higher energy transfer was observed in the WT compared to its corresponding negative control [WT vs. WT (one Prim Ab); $p \leq 0.05$, **Figure 2B**]. In addition, analysis of striatal D₂R KO tissue did not result in a significant difference in signal with or without adding primary antibodies (**Figure 2B**). These results support the existence of the interaction (or at least the very close proximity) between D₂R and M₁R in native tissue, namely, the mouse striatum.


Multimodal D₂R Agonist and M₁R Antagonist Treatment of Reserpinized Mice


The data obtained in HEK293T cells and striatal slices support the notion that D₂R and M₁R might physically interact in the striatum. Therefore, we hypothesized that this receptor–receptor interaction might constitute a molecular target for multimodal pharmacological interventions finely controlling striatal motor

activity. Accordingly, we tested the effects of a combined drug treatment regimen (D₂R agonist + M₁R antagonist) in a well-known model of movement disorder, i.e., the reserpinized mouse (Leao et al., 2015; Leal et al., 2016). The drugs used were the D₂R-selective agonist sumanirole and the M₁R-selective antagonist VU0255035. Sumanirole was chosen as it shows 200-fold more selectivity for D₂R than for other DA receptors subtypes and as it has been used both in human patients and animal models of PD (McCall et al., 2005; Stephenson et al., 2005; Barone et al., 2007). Similarly, the competitive orthosteric antagonist VU0255035 has a 75-fold higher selectivity for M₁R over other mAChR subtypes (Sheffler et al., 2009). In addition, both compounds have already been tested individually in reserpine-treated animals (McCall et al., 2005; Xiang et al., 2012).

First, we evaluated the effects of the D₂R agonist sumanirole. Mice were treated with reserpine (3 mg/kg, s.c., overnight) and, thereafter, with the selective D₂R agonist. Interestingly, sumanirole only promoted an increase in locomotion at the highest dose (10 mg/kg) (**Supplementary Figure S3**). Similarly, only at 10 mg/kg, sumanirole blocked the cataleptic effects induced by reserpine, while a slight but non-significant reduction of TJMs was observed (**Supplementary Figure 3**). Thus, based on these data, we selected 3 mg/kg of sumanirole (i.e., subthreshold dose) for further multimodal experiments in combination with the M₁R antagonist VU0255035. A dosage of 10 mg/kg of VU0255035 was selected based both on a pilot study and its pharmacokinetic profile. According to Sheffler et al. (2009), 10 mg/kg VU0255035 (i.p.) was sufficient to cross the blood-brain barrier, with maximal M₁R inhibition after 30 min, with an elimination half-life of ~2.5 h in the brain. In addition, this concentration was also reported to not impair contextual fear conditioning, a model for hippocampus-dependent learning (Sheffler et al., 2009).

In animals that received the combined treatment with VU0255035 and sumanirole (VU + SUM; 10 and 3 mg/kg, i.p.) we observed a significant ($p \leq 0.05$) reversal of the reserpine-induced akinesia (**Figure 3**). In contrast, in none of the animals treated with VU or SUM alone the akinetic status was reversed (**Figure 3A**). Our findings suggest a fine balance in locomotor activity between reserpine-induced akinesia and VU + SUM treatment. It is interesting to note that the VU + SUM-administered animals showed an increase in locomotor activity after ~25 min, which is in accordance with the pharmacokinetic profile of VU (**Figure 3B**). Thus, significant differences in locomotion were observed between the VU + SUM-treated group compared to the groups receiving a single treatment. In line with the results obtained while evaluating locomotion, a significant reduction in reserpine-induced catalepsy was observed in VU + SUM-treated mice compared to those that were administered a single agent (**Figure 3C**). However, while the simultaneous VU0255035 and sumanirole administration reduced TJMs as compared to vehicle, when compared to single administered animals, no differences were found with VU0255035-treated reserpinized mice (**Figure 3D**). Therefore, a low dose of sumanirole was unable to potentiate the VU0255035-mediated TJMs reduction. This lack of sumanirole-mediated potentiation of VU0255035 effect might be due to the fact





that 10 mg/kg VU0255035 already induced a slight, but not significant ($p = 0.1712$), reduction in TJMs. Of course, it would be reasonable to speculate that M₁Rs located within neuronal circuits controlling distinct behavioral responses might have different efficacies. Overall, our data support the use of low D₂R agonist doses in combination with an M₁R antagonist as a novel multimodal antiparkinsonian pharmacotherapy.

DISCUSSION

In the last years, G protein-coupled receptor (GPCR) oligomers have gained interest as novel putative targets for several diseases. One of the most well-characterized D₂R-containing oligomers is the D₂R/A_{2A}R heteromer in the striatum, where reciprocal antagonistic interactions both at the binding and effector levels occur between these receptors (Ferré et al., 2018). Importantly,

this functional interplay grounded the utility of A_{2A}R blockade in PD treatment, which recently ended with the approval of a selective A_{2A}R antagonist, istradefylline (Nourianz), as an adjuvant drug in PD treatment. Interestingly, while a variety of D₂R oligomer complexes has been described (Marcellino et al., 2008; Trifilieff et al., 2011; Bonaventura et al., 2014; Borroto-Escuela et al., 2014; Hasbi et al., 2017), few studies exist for M₁R (Goin and Nathanson, 2006; Hern et al., 2010). In the present study, we have observed, for the first time, the existence of striatal D₂R and M₁R complexes. In addition, we provide data supporting a novel multimodal antiparkinsonian treatment, consisting of the use of low D₂R agonist doses in combination with M₁R antagonists. Thus, our results may prompt further investigating these receptor complexes as interesting targets to modulate dopaminergic neurotransmission in dopamine-related diseases (i.e., PD) (Hersch et al., 1994; Surmeier et al., 2007; Fuxe et al., 2012).

As described for the D₂R/A_{2A}R heteromer, both M₁R and D₂R are expressed at postsynaptic membranes of striatopallidal MSNs. Thus, the avidity of D₂R to heteromerize with a named GPCR (i.e., A_{2A}R, mGlu₅R or M₁R) within this specific subcellular domain may depend on the absolute expression of specific protomers and the relative affinities shown for each receptor–receptor interaction. Importantly, the density of each individual D₂R containing oligomer may be altered in disease conditions, which may constitute a putative pathological fingerprint. Precisely, we recently reported that D₂R/A_{2A}R heteromers would be increased in the caudate from human postmortem PD patients (Fernandez-Duenas et al., 2019). This fact would negatively affect dopaminergic neurotransmission, thus providing the rationale for using A_{2A}R antagonists in PD (see above). Of note, whether the decrease in heteromer formation is a cause or a consequence of PD pathology, or even treatment, needs to be further elucidated. Here, we demonstrated the existence of D₂R–M₁R complexes in the striatum and its potential pharmacotherapeutic usefulness using an animal model of PD. However, further studies should be conducted to determine: (i) D₂R/M₁R heteromer status in human PD striatum (i.e., increase or decrease in the proportion of D₂R and M₁R protomers forming homomers or heteromers) and (ii) the molecular and functional interplay with other striatal D₂R-containing oligomers (i.e., D₂R/A_{2A}R heteromers). Certainly, establishing the D₂R-containing heteromer status in PD could determine the design of selective combined pharmacotherapeutic strategies restoring the unbalanced dopaminergic neurotransmission associated with PD.

In our study, the functional interplay between D₂R and M₁R was demonstrated by the co-administration of a D₂R agonist and an M₁R antagonist to reserpinized mice, which is an animal model mimicking parkinsonian motor and non-motor impairments (Leao et al., 2015; Leal et al., 2016). The major disadvantage of this model is the lack of dopaminergic neurons degeneration and protein aggregation. Nevertheless, reserpine-treated rodents have been successfully applied to predict the efficacy of many dopaminergic and non-dopaminergic drugs (e.g., benzotropine), which are clinically in use for PD management. The high predictive validity of this model results in the maintenance of its position as a valid choice to discover novel therapeutics in an early preclinical stage (Duty and Jenner, 2011). Other advantages are its low toxicity, low cost, and its reproducibility among laboratories (Leao et al., 2015). Furthermore, the reserpine animal model was one of the first models used to demonstrate the therapeutic efficacy of L-DOPA, which still remains the criterion standard in PD therapy (Carlsson et al., 1957). Now, D₂R selective agonists are also included in the pharmacotherapeutic munition in PD management. Of note, although the full D₂R agonist sumanirole has a high affinity for D₂R, it also has a moderate affinity for the serotonin 5-HT_{1A} receptor ($K_i = 95$ nM) (Heier et al., 1997; Wuts, 1999; McCall et al., 2005). However, according to Weber et al. (2010), the suboptimal sumanirole concentration applied in our study should not result in 5-HT_{1A} receptor off-target effects (Weber et al., 2010). It is worth mentioning that

our results, using a suboptimal concentration of sumanirole, are not in line with the findings of another study, which also used a reserpine animal model (McCall et al., 2005). The discrepancy could be owing to differences in species (mice vs. rats), reserpine inductions (3 mg/kg vs. 5 mg/kg + AMPT), administration routes of sumanirole (i.p. vs. s.c.), and/or time of reserpine pretreatments (20.5 vs. 18 h). Nevertheless, a long-term effect in locomotion at high sumanirole doses was demonstrated in both studies, which has been suggested to be the result of postsynaptic D₂R activation (McCall et al., 2005). On the other hand, the administered dose of the competitive orthosteric M₁R antagonist VU0255035 results in maximal receptor inhibition, with a high brain penetration after 30 min, without impairment in hippocampus-dependent learning tasks (Sheffler et al., 2009). The combined treatment increased locomotor activity and decreased the time of catalepsy and the amount of TJMs in our animal model, whereas the reduction in TJMs was mostly due to the M₁R antagonist (Lees, 2005; Pedrosa and Timmermann, 2013).

The dysregulation of dopaminergic or cholinergic systems has been linked to movement disorders, such as dystonia, Huntington disease, or PD (Pisani et al., 2007). Nowadays, at the early stages, PD therapy is commonly initiated with D₂R agonists, which do not require carrier-mediated transport or produce potentially toxic metabolites and free radicals (Hagan et al., 1997; Jenner, 2003). However, D₂R agonists may elicit severe adverse effects such as valvular heart disease or psychiatric disturbances (Lees, 2005; Hisahara and Shimohama, 2011; Pedrosa and Timmermann, 2013), which are probably induced by activating D₃Rs and D₄Rs (Rich et al., 1995; McCall et al., 2005). Despite its high D₂R selectivity, sumanirole has not demonstrated a clinical improvement over ropinirole (Barone et al., 2007; Singer et al., 2007). However, as suggested by the present study, sumanirole remains a valuable tool in lead optimization, drug discovery, and animal models, where the novel D₂R–M₁R interaction may provide a rationale to target specific receptor subtypes in the treatment of PD. In addition, reducing the amount of D₂R agonist by supplementing an M₁R selective antagonist (i.e., VU0255035) in a multimodal pharmacological approach may allow achieving an effective treatment and induce less adverse effects.

Muscarinic acetylcholine receptors play important roles in cognitive, motor, behavioral, sensory, and autonomic processes. Thus, non-selective blockade of mAChRs is associated with important side effects, including cognitive deficits. While scopolamine, a non-selective mAChR antagonist, robustly increased locomotor activity in reserpinized akinetic rats, it induced learning and memory impairments (Sheffler et al., 2009; Xiang et al., 2012). Importantly, most cognitive adverse effects observed with anticholinergic therapies are likely due to the result of M₂R and M₃R blockade (Fornari et al., 2000; Wess et al., 2007). Conversely, the selective M₁R blockade has been shown to exhibit some antiparkinsonian activity, although without the full efficacy as observed with non-selective anticholinergics (Xiang et al., 2012; Lv et al., 2017; Chambers et al., 2019). This is probably due to activation of other mAChRs, which also have important roles in the motor circuits of the basal ganglia (e.g., M₄R). Indeed,

antagonizing M₁R mainly has an excitatory effect on GABAergic MSNs, but no or only a partial effect at the subthalamic nucleus and substantia nigra pars reticulata (Xiang et al., 2012; Lv et al., 2017). Interestingly, mice lacking M₁R have increased locomotor activity (Gerber et al., 2001; Miyakawa et al., 2001). These M₁R KO mice also have increased extracellular dopamine levels in the striatum, which suggests that inhibiting M₁R positively affects PD treatment (Gerber et al., 2001). Moreover, M₁R KO mice were shown to maintain contextual fear recognition, which indicates that M₁R might not be involved in the initial stability of memory or in its formation in the hippocampus (Miyakawa et al., 2001; Anagnostaras et al., 2003). Accordingly, the main benefit to target M₁R over other mAChRs is due to its selective role in controlling locomotor activity, whereas its input is less critical for cognitive processes (Miyakawa et al., 2001).

In conclusion, here we demonstrated, for the first time, an interaction between D₂R and M₁R. Interestingly, our results suggest an extensive integration of dopaminergic and cholinergic neurotransmission systems in the striatum, where inhibition by DA is predicted to facilitate locomotor activity, and activation by ACh inhibits locomotion via striatopallidal MSNs (Di Chiara et al., 1994). Using reserpinized mice as a model, we demonstrated the effectiveness of a multimodal treatment, combining a suboptimal dosage of the selective D₂R agonist sumanirole and the M₁R-specific antagonist VU0255035. Overall, further functional exploitation of this novel D₂R–M₁R interaction (i.e., identifying the functional fingerprint of this putative new heterodimer in native tissue) may provide beneficial opportunities in PD treatment.

DATA AVAILABILITY STATEMENT

All datasets generated for this study are included in the article/[Supplementary Material](#).

ETHICS STATEMENT

The animal study was reviewed and approved by the Ethical Committee on Animal Use and Care of the University of Barcelona (CEEA/UB).

AUTHOR CONTRIBUTIONS

RC performed and designed the experiments, analyzed the data and wrote the manuscript. EW performed the NanoBiT[®] assay, MV-L performed the AlphaLISA[®] assay. JT and CM performed *in vivo* experiments. VF-D designed the experiments and wrote the manuscript. CS supervised the project and wrote the manuscript. FC supervised the project, designed experiments and wrote the manuscript.

FUNDING

This work was supported by the Fonds Wetenschappelijk Onderzoek (FWO-SBO, Grant number 140028), Fundació

la Marató de TV3 (Grant number 20152031), Ministerio de Ciencia, Innovación y Universidades–Agencia Estatal de Investigación/FEDER (SAF2017-87349-R) and Generalitat de Catalunya (2017 SGR 1604 and 2017 SGR 595). We thank Centres de Recerca de Catalunya (CERCA) Programme/Generalitat de Catalunya for IDIBELL institutional support. RC was also supported by an EMBO Short-Term Fellowship (Grant number 6735) and an FWO Travel Grant for a Long Stay Abroad (Grant number V420718N).

ACKNOWLEDGMENTS

The authors thank Dr. Benjamín Torrejón-Escribano, from the CCiT-UB from Bellvitge Campus of the University of Barcelona, for the technical support during the confocal microscopy imaging.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fphar.2020.00194/full#supplementary-material>

FIGURE S1 | Validation of the anti-D₂R and anti-M₁R antibodies via double immunofluorescence staining in mice brains. Images of coronal slices from mice brains representing the dorsal striatum, corpus callosum and cortex with staining of D₂R-positive cells (green), M₁R-positive cells (red) and DAPI-positive nuclei (blue). Minimal signal intensities were observed with the anti-D₂R and anti-M₁R antibodies in the D₂R and M₁R KO mice, respectively. Data shown are representative of two independent experiments. Scale bar = 100 μm.

FIGURE S2 | Validation of the anti-D₂R and anti-M₁R antibodies via Western Blotting. **(A)** The anti-D₂R antibody used in our study demonstrates specificity for D₂R in striatal tissue. Extracts of the striatum from D₂R KO, D₂R heterozygous (HET), and wild-type (WT) CD-1 littermates were loaded on 10% SDS-PAGE. The anti-α-Tubulin antibody was used to control for equal loading of the samples. **(B)** The anti-M₁R antibody used in the study demonstrates specificity for M₁R in striatal tissue. Striatal extracts from M₁R KO and wild-type (WT) with C57BL/6J background were loaded on 10% SDS-PAGE. The anti-α-Tubulin antibody was used to control for equal loading of the samples. kDa = kilodalton.

FIGURE S3 | Sumanirole dosage-response of reserpine-induced motor disturbances in mice. The mice were treated with VEH (saline and 5% Tween, i.p.), or 1, 3, or 10 mg/kg SUM (sumanirole, 1, 3, 10 mg/kg, respectively, i.p.) after reserpine administration (3 mg/kg, s.c., 20.5 ± 2 h), and evaluated via the **(A,B)** locomotor activity test, **(C)** horizontal bar test and **(D)** for tremulous jaw movements (TJMs). **(A)** The total distance traveled (cm) was measured for 85 min. Results are presented as mean ± SEM (*n* = 7–8 animals). Statistical significance was tested using one-way ANOVA, followed by the Dunnett *post hoc* test, with VEH, 1 SUM, and 3 SUM compared to 10 SUM animals, ****p* ≤ 0.01. **(B)** The distance traveled (cm) was measured every 5 min for 85 min. Results are presented as mean ± SEM (*n* = 7–8 animals). Statistical significance was tested using two-way repeated-measures ANOVA followed by the Tukey *post hoc* test, with VEH, 1 SUM, and 3 SUM compared to 10 SUM animals, **p* ≤ 0.05, ***p* ≤ 0.01, ****p* ≤ 0.001 and *****p* ≤ 0.0001. **(C)** Reserpine-induced catalepsy in mice evaluated via the horizontal bar test, with cut-off value of 120 s. Results are presented as mean ± SEM (*n* = 7–8 animals). Statistical significance was tested using one-way ANOVA followed by the Tukey *post hoc* test, ***p* ≤ 0.01. **(D)** Reserpine-induced orofacial dyskinesia evaluated by TJMs for 10 min. Results are presented as mean ± SEM (*n* = 7–8 animals). Statistical significance was tested using one-way ANOVA followed by the Tukey *post hoc* test, ***p* ≤ 0.01.

REFERENCES

- Anagnostaras, S. G., Murphy, G. G., Hamilton, S. E., Mitchell, S. L., Rahnama, N. P., Nathanson, N. M., et al. (2003). Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. *Nat. Neurosci.* 6, 51–58. doi: 10.1038/nn992
- Barone, P., Lamb, J., Ellis, A., and Clarke, Z. (2007). Sumanriole versus placebo or ropinirole for the adjunctive treatment of patients with advanced Parkinson's disease. *Mov. Disord.* 22, 483–489. doi: 10.1002/mds.21191
- Bolam, J. P., Wainer, B. H., and Smith, A. D. (1984). Characterization of cholinergic neurons in the rat neostriatum. A combination of choline acetyltransferase immunocytochemistry, Golgi-impregnation and electron microscopy. *Neuroscience* 12, 711–718. doi: 10.1016/0306-4522(84)90165-9
- Bonaventura, J., Rico, A. J., Moreno, E., Sierra, S., Sanchez, M., Luquin, N., et al. (2014). L-DOPA-treatment in primates disrupts the expression of A(2A) adenosine-CB(1) cannabinoid-D(2) dopamine receptor heteromers in the caudate nucleus. *Neuropharmacology* 79, 90–100. doi: 10.1016/j.neuropharm.2013.10.036
- Bordia, T., and Perez, X. A. (2019). Cholinergic control of striatal neurons to modulate L-DOPA-induced dyskinesias. *Eur. J. Neurosci.* 49, 859–868. doi: 10.1111/ejn.14048
- Borrotto-Escuela, D. O., Romero-Fernandez, W., Garriga, P., Ciruela, F., Narvaez, M., Tarakanov, A. O., et al. (2013). G protein-coupled receptor heterodimerization in the brain. *Methods Enzymol.* 521, 281–294. doi: 10.1016/B978-0-12-391862-8.00015-6
- Borrotto-Escuela, D. O., Romero-Fernandez, W., Narvaez, M., Oflijan, J., Agnati, L. F., and Fuxe, K. (2014). Hallucinogenic 5-HT2AR agonists LSD and DOI enhance dopamine D2R protomer recognition and signaling of D2-5-HT2A heteroreceptor complexes. *Biochem. Biophys. Res. Commun.* 443, 278–284. doi: 10.1016/j.bbrc.2013.11.104
- Cabello, N., Gandia, J., Bertarelli, D. C., Watanabe, M., Lluís, C., Franco, R., et al. (2009). Metabotropic glutamate type 5, dopamine D2 and adenosine A2a receptors form higher-order oligomers in living cells. *J. Neurochem.* 109, 1497–1507. doi: 10.1111/j.1471-4159.2009.06078.x
- Calabresi, P., Centonze, D., Gubellini, P., Pisani, A., and Bernardi, G. (2000). Acetylcholine-mediated modulation of striatal function. *Trends Neurosci.* 23, 120–126. doi: 10.1016/S0166-2236(99)01501-5
- Cannaert, A., Storme, J., Franz, F., Auwärter, V., and Stove, C. P. (2016). Detection and activity profiling of synthetic cannabinoids and their metabolites with a newly developed bioassay. *Anal. Chem.* 88, 11476–11485. doi: 10.1021/acs.analchem.6b02600
- Carlsson, A., Lindqvist, M., and Magnusson, T. (1957). 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. *Nature* 180:1200. doi: 10.1038/1801200a0
- Chambers, N. E., Meadows, S. M., Taylor, A., Sheena, E., Lanza, K., Conti, M. M., et al. (2019). Effects of muscarinic acetylcholine M1 and M4 receptor blockade on dyskinesia in the hemi-parkinsonian rat. *Neuroscience* 409, 180–194. doi: 10.1016/j.neuroscience.2019.04.008
- Chen, J. J., and Swope, D. M. (2007). Pharmacotherapy for Parkinson's disease. *Pharmacotherapy* 27(12 Pt 2), 161S–173S. doi: 10.1592/phco.27.12part2.161S
- Clark, J. D., Gebhart, G. F., Gonder, J. C., Keeling, M. E., and Kohn, D. F. (1997). Special report: the 1996 guide for the care and use of laboratory animals. *ILAR J.* 38, 41–48.
- Contant, C., Umbriaco, D., Garcia, S., Watkins, K. C., and Descarries, L. (1996). Ultrastructural characterization of the acetylcholine innervation in adult rat neostriatum. *Neuroscience* 71, 937–947. doi: 10.1016/0306-4522(95)00507-2
- Cottet, M., Faklaris, O., Maurel, D., Scholler, P., Doumazane, E., Trinquet, E., et al. (2012). BRET and time-resolved FRET strategy to study GPCR oligomerization: from cell lines toward native tissues. *Front. Endocrinol. (Lausanne)* 3:92. doi: 10.3389/fendo.2012.00092
- Dacres, H., Michie, M., Wang, J., Pflieger, K. D., and Trowell, S. C. (2012). Effect of enhanced *Renilla* luciferase and fluorescent protein variants on the forster distance of bioluminescence resonance energy transfer (BRET). *Biochem. Biophys. Res. Commun.* 425, 625–629. doi: 10.1016/j.bbrc.2012.07.133
- Dexter, D. T., and Jenner, P. (2013). Parkinson disease: from pathology to molecular disease mechanisms. *Free Radic. Biol. Med.* 62, 132–144. doi: 10.1016/j.freeradbiomed.2013.01.018
- Di Chiara, G., Morelli, M., and Consolo, S. (1994). Modulatory functions of neurotransmitters in the striatum: ACh/dopamine/NMDA interactions. *Trends Neurosci.* 17, 228–233. doi: 10.1016/0166-2236(94)90005-1
- Duty, S., and Jenner, P. (2011). Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. *Br. J. Pharmacol.* 164, 1357–1391. doi: 10.1111/j.1476-5381.2011.01426.x
- Fernandez-Duenas, V., Gomez-Soler, M., Valle-Leon, M., Watanabe, M., Ferrer, I., and Ciruela, F. (2019). Revealing adenosine A2A-dopamine D2 receptor heteromers in Parkinson's disease post-mortem brain through a new alphaScreen-based assay. *Int. J. Mol. Sci.* 20:3600. doi: 10.3390/ijms20143600
- Fernandez-Duenas, V., Taura, J. J., Cottet, M., Gomez-Soler, M., Lopez-Cano, M., Ledent, C., et al. (2015). Untangling dopamine-adenosine receptor-receptor assembly in experimental parkinsonism in rats. *Dis. Model Mech.* 8, 57–63. doi: 10.1242/dmm.018143
- Ferré, S., Bonaventura, J., Zhu, W., Hatcher-Solis, C., Taura, J., Quiroz, C., et al. (2018). Essential control of the function of the striatopallidal neuron by pre-coupled complexes of adenosine A2A-dopamine D2 receptor heterotetramers and adenylyl cyclase. *Front. Pharmacol.* 9:243. doi: 10.3389/fphar.2018.00243
- Fisahn, A., Yamada, M., Duttaroy, A., Gan, J. W., Deng, C. X., McBain, C. J., et al. (2002). Muscarinic induction of hippocampal gamma oscillations requires coupling of the M1 receptor to two mixed cation currents. *Neuron* 33, 615–624. doi: 10.1016/S0896-6273(02)00587-1
- Fornari, R. V., Moreira, K. M., and Oliveira, M. G. (2000). Effects of the selective M1 muscarinic receptor antagonist dicyclomine on emotional memory. *Learn. Mem.* 7, 287–292. doi: 10.1101/lm.34900
- Fox, S. H., Katzenschlager, R., Lim, S. Y., Barton, B., de Bie, R. M. A., Seppi, K., et al. (2018). International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease. *Mov. Disord.* 33, 1248–1266. doi: 10.1002/mds.27372
- Fox, S. H., Katzenschlager, R., Lim, S. Y., Ravina, B., Seppi, K., Coelho, M., et al. (2011). The movement disorder society evidence-based medicine review update: treatments for the motor symptoms of Parkinson's disease. *Mov. Disord.* 26(Suppl. 3), S2–S41. doi: 10.1002/mds.23829
- Fuxe, K., Borrotto-Escuela, D. O., Romero-Fernandez, W., Diaz-Cabiale, Z., Rivera, A., Ferraro, L., et al. (2012). Extrasynaptic neurotransmission in the modulation of brain function. Focus on the striatal neuronal-glial networks. *Front. Physiol.* 3:136. doi: 10.3389/fphys.2012.00136
- Gagnon, D., Petryszyn, S., Sanchez, M. G., Bories, C., Beaulieu, J. M., De Koninck, Y., et al. (2017). Striatal neurons expressing D1 and D2 receptors are morphologically distinct and differently affected by dopamine denervation in mice. *Sci. Rep.* 7:41432. doi: 10.1038/srep41432
- Gerber, D. J., Sotnikova, T. D., Gainetdinov, R. R., Huang, S. Y., Caron, M. G., and Tonegawa, S. (2001). Hyperactivity, elevated dopaminergic transmission, and response to amphetamine in M1 muscarinic acetylcholine receptor-deficient mice. *Proc. Natl. Acad. Sci. U.S.A.* 98, 15312–15317. doi: 10.1073/pnas.261583798
- Goin, J. C., and Nathanson, N. M. (2006). Quantitative analysis of muscarinic acetylcholine receptor homo- and heterodimerization in live cells: regulation of receptor down-regulation by heterodimerization. *J. Biol. Chem.* 281, 5416–5425. doi: 10.1074/jbc.M507476200
- Graybiel, A. M. (1990). Neurotransmitters and neuromodulators in the basal ganglia. *Trends Neurosci.* 13, 244–254. doi: 10.1016/0166-2236(90)90104-i
- Hagan, J. J., Middlemiss, D. N., Sharpe, P. C., and Poste, G. H. (1997). Parkinson's disease: prospects for improved drug therapy. *Trends Pharmacol. Sci.* 18, 156–163. doi: 10.1016/S0165-6147(97)90612-x
- Hasbi, A., Perreault, M. L., Shen, M. Y. F., Fan, T., Nguyen, T., Alijaniam, M., et al. (2017). Activation of dopamine D1-D2 receptor complex attenuates cocaine reward and reinstatement of cocaine-seeking through inhibition of DARPP-32, ERK, and deltaFosB. *Front. Pharmacol.* 8:924. doi: 10.3389/fphar.2017.00924
- Heier, R. F., Dolak, L. A., Duncan, J. N., Hyslop, D. K., Lipton, M. F., Martin, I. J., et al. (1997). Synthesis and biological activities of (R)-5,6-dihydro-N,N-dimethyl-4H-imidazo[4,5,1-ij]quinolin-5-amine and its metabolites. *J. Med. Chem.* 40, 639–646. doi: 10.1021/jm960360q

- Hern, J. A., Baig, A. H., Mashanov, G. I., Birdsall, B., Corrie, J. E., Lazareno, S., et al. (2010). Formation and dissociation of M1 muscarinic receptor dimers seen by total internal reflection fluorescence imaging of single molecules. *Proc. Natl. Acad. Sci. U.S.A.* 107, 2693–2698. doi: 10.1073/pnas.0907915107
- Hersch, S. M., Gutekunst, C. A., Rees, H. D., Heilman, C. J., and Levey, A. I. (1994). Distribution of M1-M4 muscarinic receptor proteins in the rat striatum: light and electron microscopic immunocytochemistry using subtype-specific antibodies. *J. Neurosci.* 14(5 Pt 2), 3351–3363. doi: 10.1523/jneurosci.14-05-03351.1994
- Hisahara, S., and Shimohama, S. (2011). Dopamine receptors and Parkinson's disease. *Int. J. Med. Chem.* 2011:403039. doi: 10.1155/2011/403039
- Jenner, P. (2003). Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson's disease. *Curr. Opin. Neurol.* 16(Suppl. 1), S3–S7.
- Kalia, L. V., and Lang, A. E. (2015). Parkinson's disease. *Lancet* 386, 896–912. doi: 10.1016/S0140-6736(14)61393-3
- Katzenschlager, R., Sampaio, C., Costa, J., and Lees, A. (2003). Anticholinergics for symptomatic management of Parkinson's disease. *Cochrane Database Syst. Rev.* 2:CD003735. doi: 10.1002/14651858.CD003735
- Leal, P. C., Lins, L. C., de Gois, A. M., Marchioro, M., and Santos, J. R. (2016). Commentary: evaluation of models of Parkinson's disease. *Front. Neurosci.* 10:283. doi: 10.3389/fnins.2016.00283
- Leao, A. H., Sarmiento-Silva, A. J., Santos, J. R., Ribeiro, A. M., and Silva, R. H. (2015). Molecular, neurochemical, and behavioral hallmarks of reserpine as a model for Parkinson's disease: new perspectives to a long-standing model. *Brain Pathol.* 25, 377–390. doi: 10.1111/bpa.12253
- Lees, A. (2005). Alternatives to levodopa in the initial treatment of early Parkinson's disease. *Drugs Aging* 22, 731–740. doi: 10.2165/00002512-200522090-00002
- Lukasiewicz, S., Polit, A., Kedracka-Krok, S., Wedzony, K., Mackowiak, M., and Dziedzicka-Wasylewska, M. (2010). Hetero-dimerization of serotonin 5-HT(2A) and dopamine D(2) receptors. *Biochim. Biophys. Acta* 1803, 1347–1358. doi: 10.1016/j.bbamcr.2010.08.010
- Lv, X., Dickerson, J. W., Rook, J. M., Lindsley, C. W., Conn, P. J., and Xiang, Z. (2017). M1 muscarinic activation induces long-lasting increase in intrinsic excitability of striatal projection neurons. *Neuropharmacology* 118, 209–222. doi: 10.1016/j.neuropharm.2017.03.017
- Marcellino, D., Carriba, P., Filip, M., Borgkvist, A., Frankowska, M., Bellido, I., et al. (2008). Antagonistic cannabinoid CB1/dopamine D2 receptor interactions in striatal CB1/D2 heteromers. A combined neurochemical and behavioral analysis. *Neuropharmacology* 54, 815–823. doi: 10.1016/j.neuropharm.2007.12.011
- Massari, C. M., Lopez-Cano, M., Nunez, F., Fernandez-Duenas, V., Tasca, C. I., and Ciruela, F. (2017). Antiparkinsonian efficacy of guanosine in rodent models of movement disorder. *Front. Pharmacol.* 8:700. doi: 10.3389/fphar.2017.00700
- McCall, R. B., Lookingland, K. J., Bedard, P. J., and Huff, R. M. (2005). Sumanitrole, a highly dopamine D2-selective receptor agonist: in vitro and in vivo pharmacological characterization and efficacy in animal models of Parkinson's disease. *J. Pharmacol. Exp. Ther.* 314, 1248–1256. doi: 10.1124/jpet.105.084202
- Mesulam, M. M., Mash, D., Hersh, L., Bothwell, M., and Geula, C. (1992). Cholinergic innervation of the human striatum, globus pallidus, subthalamic nucleus, substantia nigra, and red nucleus. *J. Comp. Neurol.* 323, 252–268. doi: 10.1002/cne.903230209
- Mhyre, T. R., Boyd, J. T., Hamill, R. W., and Maguire-Zeiss, K. A. (2012). Parkinson's disease. *Subcell Biochem.* 65, 389–455. doi: 10.1007/978-94-007-5416-4_16
- Miyakawa, T., Yamada, M., Duttaroy, A., and Wess, J. (2001). Hyperactivity and intact hippocampus-dependent learning in mice lacking the M1 muscarinic acetylcholine receptor. *J. Neurosci.* 21, 5239–5250. doi: 10.1523/jneurosci.21-14-05239.2001
- Pedrosa, D. J., and Timmermann, L. (2013). Review: management of Parkinson's disease. *Neuropsychiatr. Dis. Treat.* 9, 321–340. doi: 10.2147/NDT.S32302
- Pisani, A., Bernardi, G., Ding, J., and Surmeier, D. J. (2007). Re-emergence of striatal cholinergic interneurons in movement disorders. *Trends Neurosci.* 30, 545–553. doi: 10.1016/j.tins.2007.07.008
- Rich, S. S., Friedman, J. H., and Ott, B. R. (1995). Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. *J. Clin. Psychiatry* 56, 556–559.
- Rico, A. J., Dopeso-Reyes, I. G., Martinez-Pinilla, E., Sucunza, D., Pignataro, D., Roda, E., et al. (2017). Neurochemical evidence supporting dopamine D1-D2 receptor heteromers in the striatum of the long-tailed macaque: changes following dopaminergic manipulation. *Brain Struct. Funct.* 222, 1767–1784. doi: 10.1007/s00429-016-1306-x
- Salamone, J. D., Mayorga, A. J., Trevitt, J. T., Cousins, M. S., Conlan, A., and Nawab, A. (1998). Tremulous jaw movements in rats: a model of parkinsonian tremor. *Prog. Neurobiol.* 56, 591–611. doi: 10.1016/s0301-0082(98)00053-7
- Sheffler, D. J., Williams, R., Bridges, T. M., Xiang, Z., Kane, A. S., Byun, N. E., et al. (2009). A novel selective muscarinic acetylcholine receptor subtype 1 antagonist reduces seizures without impairing hippocampus-dependent learning. *Mol. Pharmacol.* 76, 356–368. doi: 10.1124/mol.109.056531
- Shen, W., Plotkin, J. L., Francardo, V., Ko, W. K., Xie, Z., Li, Q., et al. (2015). M4 muscarinic receptor signaling ameliorates striatal plasticity deficits in models of L-DOPA-induced dyskinesia. *Neuron* 88, 762–773. doi: 10.1016/j.neuron.2015.10.039
- Singer, C., Lamb, J., Ellis, A., Layton, G., and Sumanitrole for Early Parkinson's Disease Study Group (2007). A comparison of sumanitrole versus placebo or ropinireole for the treatment of patients with early Parkinson's disease. *Mov. Disord.* 22, 476–482. doi: 10.1002/mds.21361
- Stephenson, D. T., Meglasson, M. D., Connell, M. A., Childs, M. A., Hajos-Korcsok, E., and Emborg, M. E. (2005). The effects of a selective dopamine D2 receptor agonist on behavioral and pathological outcome in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated squirrel monkeys. *J. Pharmacol. Exp. Ther.* 314, 1257–1266. doi: 10.1124/jpet.105.087379
- Surmeier, D. J., Ding, J., Day, M., Wang, Z., and Shen, W. (2007). D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons. *Trends Neurosci.* 30, 228–235. doi: 10.1016/j.tins.2007.03.008
- Taura, J., Valle-Leon, M., Sahlholm, K., Watanabe, M., Van Craenenbroeck, K., Fernandez-Duenas, V., et al. (2017). Behavioral control by striatal adenosine A2A-dopamine D2 receptor heteromers. *Genes Brain Behav.* 17:e12432. doi: 10.1111/gbb.12432
- Trifilieff, P., Rives, M. L., Urizar, E., Piskowski, R. A., Vishwasrao, H. D., Castrillon, J., et al. (2011). Detection of antigen interactions ex vivo by proximity ligation assay: endogenous dopamine D2-adenosine A2A receptor complexes in the striatum. *Biotechniques* 51, 111–118. doi: 10.2144/000113719
- Tsukada, H., Harada, N., Nishiyama, S., Ohba, H., and Kakiuchi, T. (2000). Cholinergic neuronal modulation alters dopamine D2 receptor availability in vivo by regulating receptor affinity induced by facilitated synaptic dopamine turnover: positron emission tomography studies with microdialysis in the conscious monkey brain. *J. Neurosci.* 20, 7067–7073. doi: 10.1523/jneurosci.20-18-07067.2000
- Vasudevan, L., Borroto-Escuela, D. O., Huysentruyt, J., Fuxe, K., Saini, D. K., and Stove, C. (2019). Heterodimerization of mu opioid receptor protomer with dopamine D2 receptor modulates agonist-induced internalization of mu opioid receptor. *Biomolecules* 9:368. doi: 10.3390/biom9080368
- Weber, M., Chang, W. L., Breier, M. R., Yang, A., Millan, M. J., and Swerdlow, N. R. (2010). The effects of the dopamine D2 agonist sumanitrole on prepulse inhibition in rats. *Eur. Neuropsychopharmacol.* 20, 421–425. doi: 10.1016/j.euroneuro.2010.02.011
- Wess, J., Egen, R. M., and Gautam, D. (2007). Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development. *Nat. Rev. Drug Discov.* 6, 721–733. doi: 10.1038/nrd2379
- Wouters, E., Marin, A. R., Dalton, J. A. R., Giraldo, J., and Stove, C. (2019a). Distinct dopamine D(2) receptor antagonists differentially impact D(2) receptor oligomerization. *Int. J. Mol. Sci.* 20:1686. doi: 10.3390/ijms20071686
- Wouters, E., Vasudevan, L., Crans, R. A. J., Saini, D. K., and Stove, C. P. (2019b). Luminescence- and fluorescence-based complementation assays to screen for GPCR oligomerization: current state of the art. *Int. J. Mol. Sci.* 20:2958. doi: 10.3390/ijms20122958
- Wuts, P. G. (1999). Synthesis of PNU-95666E. *Curr. Opin. Drug Discov. Devel.* 2, 557–564.
- Xiang, Z., Thompson, A. D., Jones, C. K., Lindsley, C. W., and Conn, P. J. (2012). Roles of the M1 muscarinic acetylcholine receptor subtype in the regulation of basal ganglia function and implications for the treatment of Parkinson's disease. *J. Pharmacol. Exp. Ther.* 340, 595–603. doi: 10.1124/jpet.111.187856

- Yan, Z., Flores-Hernandez, J., and Surmeier, D. J. (2001). Coordinated expression of muscarinic receptor messenger RNAs in striatal medium spiny neurons. *Neuroscience* 103, 1017–1024. doi: 10.1016/s0306-4522(01)00039-2
- Zhang, W., Yamada, M., Gomez, J., Basile, A. S., and Wess, J. (2002). Multiple muscarinic acetylcholine receptor subtypes modulate striatal dopamine release, as studied with M1-M5 muscarinic receptor knock-out mice. *J. Neurosci.* 22, 6347–6352. doi: 10.1523/jneurosci.22-15-06347.2002
- Ztaou, S., Maurice, N., Camon, J., Guiraudie-Capraz, G., Kerkerian-Le Goff, L., Beurrier, C., et al. (2016). Involvement of striatal cholinergic Interneurons and M1 and M4 muscarinic receptors in motor symptoms of Parkinson's disease. *J. Neurosci.* 36, 9161–9172. doi: 10.1523/JNEUROSCI.0873-16.2016

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Crans, Wouters, Valle-León, Taura, Massari, Fernández-Dueñas, Stove and Ciruela. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.